Site Search

DEUTSCH All Languages

Companies in the News

Ablynx (EBR:ABLX) ABLYNX EXPANDS ITS ANTI-THROMBOTIC PORTFOLIO AND ANNOUNCES INITIATION OF A PHASE I STUDYFOR ALX-0681

Ablynx (EBR:ABLX) GHENT, Belgium, 8 December 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that it has initiated a double-blind, randomized, placebo-controlled Phase I study in healthy volunteers with ALX-0681. The subjects will receive a subcutaneous injection of the novel anti-thrombotic Nanobody® that selectively targets von Willebrand (vWF) factor.

The Phase I study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeated subcutaneous administrations of ALX-0681. Ablynx will recruit up to 36 healthy volunteers for this study.

It is anticipated that subcutaneous administration of ALX-0681 will provide access to additional patient populations suffering from unwanted blood-clot formation, such as acute coronary syndrome (ACS), that are not currently addressed by the intravenous administration of ALX-0081. In addition, ALX-0681 is also being developed for the treatment of patients with thrombotic thrombocytopenic purpura (TTP).

"Ablynx is committed to developing its own internal pipeline of Nanobody®-based drugs and, with the positive progress to date of our lead product, ALX-0081, which also selectively targets von Willebrand factor, we are delighted to have now advanced a second product from our platform, ALX-0681, into a healthy volunteer Phase I study," commented Dr Edwin Moses, Chairman and Chief Executive Officer.

- ends -

About ALX-0681 and ALX-0081 ALX-0681 and ALX-0081 are novel "first-in-class" therapeutic Nanobodies® targeting von Willebrand factor ("vWF"), a protein found in the blood that acts at a very early stage in the coagulation cascade, namely platelet adhesion, in contrast to currently available anti-platelet drugs which act only in the late stage of platelet aggregation. ALX-0081 is administered intravenously while ALX-0681 is administered subcutaneously. ALX-0681, a new potential anti-thrombotic agent, is a bivalent Nanobody® with a molecular weight of 28,000 daltons, designed to selectively prevent unwanted thrombus formation in vessels under high shear conditions without interfering with desirable haemostasis and, as such, to minimize bleeding complications.

For more information, please contact:

College Hill Life Sciences - for UK/International media enquiries: Sue Charles, Justine Lamond, John McIntyre t: +44 (0)20 7866 7857 f: +44 (0)20 7866 7900 e: ablynx@collegehill.com

Ablynx: Dr. Edwin Moses Chairman and CEO t: +32 (0)9 262 00 07 m: +44 (0)7771 954 193 / +32 (0)473 39 50 68 e: edwin.moses@ablynx.com

Eva-Lotta Allan Chief Business Officer t: +32 (0)9 262 00 75 m: +32 (0)475 78 36 21 / +44 (0)7990 570 900 e: eva-lotta.allan@ablynx.com

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

LINK: http://hugin.info/137912/R/1275929/284073.pdf

Ablynx

http://www.ablynx.com

ISIN: BE0003877942

Stock Identifier: XBRU.ABLX

Verbundene Unternehmen

Ablynx

ABN Newswire Diese Seite wurde besucht: (letzten 7 Tagen: 4) (letzten 30 Tagen: 19) (seit Veröffentlichung: 1174)